source
- ADARx upsizes Nasdaq IPO to $446M as City Therapeutics eyes public listingADARx Pharmaceuticals, a San Diego-based RNA biotech, completed a Nasdaq initial public offering this morning, selling 26.3 million shares at $17 each. The offering generated gross proceeds of abo…
- Pharma groups urge FDA to clarify criteria for approving drugs based on a single pivotal trialPharmaceutical companies and industry associations are asking the U.S. Food and Drug Administration for more detailed guidance on when a single pivotal clinical trial, supported by additional confi…